Koji Nakagawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Koji Nakagawa has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
Rikikazu Sugiyama
Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Tokyo, Japan
37 shared publications- Keiji Kuroda
Center for Reproductive Medicine and Endoscopy, Sugiyama Clinic Marunouchi, Tokyo, Japan
17 shared publications Takashi Horikawa
Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Tokyo, Japan
15 shared publicationsRie Sugiyama
Center for Reproductive Medicine and Endoscopy Sugiyama Clinic Marunouchi Tokyo Japan
13 shared publicationsYayoi Nishi
Division of Reproductive Medicine, Sugiyama Clinic, Tokyo, Japan
13 shared publicationsYasushi Kuribayashi
Center for Reproductive Medicine and Endoscopy Sugiyama Clinic Marunouchi Tokyo Japan
12 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by World Scientific Pub Co Pte Ltd in Fertility & Reproduction
- Vol. 08 (03) , 124-131
Piezo-ICSI Reduces Oocyte Degeneration, Improves ICSI Success Rates and Has Shown Less Dependence on the Experience Level of Embryologists: Cumulative Data with 65,033 MII Oocytes
Introduction: Recent improvements in mercury-free piezo-assisted intracytoplasmic sperm injection (P-ICSI) devices have renewed interest in this technique, and reports on its usefulness are increasing. Aims: This study compares laboratory outcomes of P-ICSI and conventional ICSI (C-ICSI) and examines whether results differ by maternal age or embryologist experience. Methods: This retrospective observational cohort study included all eligible oocyte retrieval cycles performed at a single high-volume assisted reproductive technology (ART) centre (Sugiyama Clinic Shinjuku) from January 2018 to February 2023 after prespecified exclusions. A total of 15,687 cycles yielded 65,033 mature metaphase II (MII) oocytes. C-ICSI was performed from 2018 to early 2019, and P-ICSI was introduced in 2019. Outcomes included fertilisation per MII oocyte, post-ICSI oocyte degeneration and blastocyst formation per fertilised oocyte. Prespecified subgroup analyses were performed by female age ([Formula: see text]40 vs [Formula: see text]40 years) and embryologist experience (senior [Formula: see text]10 years; intermediate 5–10 years; junior [Formula: see text]5 years). Results: Amongst 65,033 MII oocytes, 13,549 underwent C-ICSI and 51,484 underwent P-ICSI. Compared with C-ICSI, P-ICSI was associated with a higher fertilisation (83.8% vs 74.8%; [Formula: see text]), lower degeneration (2.9% vs 6.9%; [Formula: see text]) and higher blastocyst formation (54.0% vs 36.3%; [Formula: see text]). These advantages persisted in women aged [Formula: see text]40 years (fertilisation 84.6% vs 75.9%; degeneration 2.8% vs 6.8%; blastocyst 58.9% vs 42.0%; all [Formula: see text]) and [Formula: see text]40 years (82.6% vs 72.8%; 3.0% vs 7.1%; 46.9% vs 25.8%; all [Formula: see text]). With C-ICSI, fertilisation decreased with less experience (77.2%, 70.6% and 63.8%; p ¡ 0.001), whereas fertilisation remained stable with P-ICSI (82.2%, 82.0% and 82.2%). Conclusions: P-ICSI is associated with improved fertilisation and blastocyst formation and reduced oocyte degeneration compared with C-ICSI, with consistent benefits across maternal age strata and reduced dependency on operator experience. These findings support broader adoption of P-ICSI as a gentler and more reproducible micromanipulation technique.
- 16 September 2026
- Published by World Scientific Pub Co Pte Ltd in Fertility & Reproduction
- Vol. 08 (03) , 124-131
Open AccessPiezo-ICSI Reduces Oocyte Degeneration, Improves ICSI Success Rates and Has Shown Less Dependence on the Experience Level of Embryologists: Cumulative Data with 65,033 MII Oocytes
Introduction: Recent improvements in mercury-free piezo-assisted intracytoplasmic sperm injection (P-ICSI) devices have renewed interest in this technique, and reports on its usefulness are increasing. Aims: This study compares laboratory outcomes of P-ICSI and conventional ICSI (C-ICSI) and examines whether results differ by maternal age or embryologist experience. Methods: This retrospective observational cohort study included all eligible oocyte retrieval cycles performed at a single high-volume assisted reproductive technology (ART) centre (Sugiyama Clinic Shinjuku) from January 2018 to February 2023 after prespecified exclusions. A total of 15,687 cycles yielded 65,033 mature metaphase II (MII) oocytes. C-ICSI was performed from 2018 to early 2019, and P-ICSI was introduced in 2019. Outcomes included fertilisation per MII oocyte, post-ICSI oocyte degeneration and blastocyst formation per fertilised oocyte. Prespecified subgroup analyses were performed by female age ([Formula: see text]40 vs [Formula: see text]40 years) and embryologist experience (senior [Formula: see text]10 years; intermediate 5–10 years; junior [Formula: see text]5 years). Results: Amongst 65,033 MII oocytes, 13,549 underwent C-ICSI and 51,484 underwent P-ICSI. Compared with C-ICSI, P-ICSI was associated with a higher fertilisation (83.8% vs 74.8%; [Formula: see text]), lower degeneration (2.9% vs 6.9%; [Formula: see text]) and higher blastocyst formation (54.0% vs 36.3%; [Formula: see text]). These advantages persisted in women aged [Formula: see text]40 years (fertilisation 84.6% vs 75.9%; degeneration 2.8% vs 6.8%; blastocyst 58.9% vs 42.0%; all [Formula: see text]) and [Formula: see text]40 years (82.6% vs 72.8%; 3.0% vs 7.1%; 46.9% vs 25.8%; all [Formula: see text]). With C-ICSI, fertilisation decreased with less experience (77.2%, 70.6% and 63.8%; p ¡ 0.001), whereas fertilisation remained stable with P-ICSI (82.2%, 82.0% and 82.2%). Conclusions: P-ICSI is associated with improved fertilisation and blastocyst formation and reduced oocyte degeneration compared with C-ICSI, with consistent benefits across maternal age strata and reduced dependency on operator experience. These findings support broader adoption of P-ICSI as a gentler and more reproducible micromanipulation technique.
- 20 December 2025
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 173, 104824
Tacrolimus treatment in reproductive failures
- 20 December 2025
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 173, 104824
Tacrolimus treatment in reproductive failures
- Open Access
- 1 September 2025
- Published by World Scientific Pub Co Pte Ltd in Fertility & Reproduction
- Vol. 07 (03) , 122-128
Estimating the Number of Retrieved Oocytes Needed to Obtain at Least One Euploid Blastocyst
Purpose: The objective of this study was to estimate the number of oocytes that need to be retrieved to obtain at least one euploid embryo (NOR-euploid) based on our clinic’s preimplantation genetic testing for aneuploidy (PGT-A) outcomes, stratified by maternal age. All patients underwent PGT-A due to recurrent pregnancy loss (RPL) or repeated implantation failure (RIF), which may not represent the general in vitro fertilization (IVF) population. Methods: A total of 4,440 oocyte pick-up (OPU) cycles performed for PGT-A at our clinic between April 2019 and May 2024 were retrospectively analyzed. RPL was defined as [ ] pregnancy losses; RIF was defined as [ ] transfers of morphologically good blastocysts without pregnancy. Euploidy rates were calculated based on the number of retrieved oocytes (NOR) within each maternal age group. The NOR-euploid was estimated for each age group using the inverse of the euploidy rate, and 95% confidence intervals (CIs) were calculated using the Wilson score method. Results: The euploidy rates per retrieved oocyte were as follows (95% CI): 18.1% (16.3–20.0) for [ ] years; 14.8% (13.7–16.0) for 31–32 years; 14.7% (13.8–15.7) for 33–34 years; 12.9% (11.8–14.0) for 35–36 years; 10.1% (9.3–10.9) for 37–38 years; 7.2% (6.6–7.9) for 39–40 years; 3.8% (3.3–4.3) for 41–42 years; and 1.1% (0.9–1.3) for [ ] years. The corresponding estimated NOR-euploid values were approximately 6, 7, 7, 8, 10, 14, 27, and 91, respectively. Conclusions: In women under 36 years of age, retrieving approximately 6–7 oocytes is, on average, sufficient to obtain at least one euploid blastocyst; however, individual prognosis may vary depending on multiple biological and clinical factors.
- 1 September 2025
- Published by World Scientific Pub Co Pte Ltd in Fertility & Reproduction
- Vol. 07 (03) , 122-128
Open AccessEstimating the Number of Retrieved Oocytes Needed to Obtain at Least One Euploid Blastocyst
Purpose: The objective of this study was to estimate the number of oocytes that need to be retrieved to obtain at least one euploid embryo (NOR-euploid) based on our clinic’s preimplantation genetic testing for aneuploidy (PGT-A) outcomes, stratified by maternal age. All patients underwent PGT-A due to recurrent pregnancy loss (RPL) or repeated implantation failure (RIF), which may not represent the general in vitro fertilization (IVF) population. Methods: A total of 4,440 oocyte pick-up (OPU) cycles performed for PGT-A at our clinic between April 2019 and May 2024 were retrospectively analyzed. RPL was defined as [ ] pregnancy losses; RIF was defined as [ ] transfers of morphologically good blastocysts without pregnancy. Euploidy rates were calculated based on the number of retrieved oocytes (NOR) within each maternal age group. The NOR-euploid was estimated for each age group using the inverse of the euploidy rate, and 95% confidence intervals (CIs) were calculated using the Wilson score method. Results: The euploidy rates per retrieved oocyte were as follows (95% CI): 18.1% (16.3–20.0) for [ ] years; 14.8% (13.7–16.0) for 31–32 years; 14.7% (13.8–15.7) for 33–34 years; 12.9% (11.8–14.0) for 35–36 years; 10.1% (9.3–10.9) for 37–38 years; 7.2% (6.6–7.9) for 39–40 years; 3.8% (3.3–4.3) for 41–42 years; and 1.1% (0.9–1.3) for [ ] years. The corresponding estimated NOR-euploid values were approximately 6, 7, 7, 8, 10, 14, 27, and 91, respectively. Conclusions: In women under 36 years of age, retrieving approximately 6–7 oocytes is, on average, sufficient to obtain at least one euploid blastocyst; however, individual prognosis may vary depending on multiple biological and clinical factors.
- 30 May 2025
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 93 (6) , e70099
2025 American Society for Reproductive Immunology Guidelines for the Treatment of Recurrent Pregnancy Losses: Practice Recommendations From the ASRI Clinical Reproductive Immunology Fellowship
Various immunomodulatory treatments have been applied to women with recurrent pregnancy losses since a significant proportion of them have cellular and autoimmune abnormalities. However, immunomodulatory treatments are often considered controversial for their efficacies. Often, they are provided to unselected patients without investigating potential etiologies by healthcare providers without appropriate reproductive immunology training and qualifications. To eliminate these concerns, the American Society for Reproductive Immunology (ASRI) established the Clinical Reproductive Immunology Fellowship and has been certifying reproductive immunologists. The approach to RPL from a reproductive immunology perspective requires a detailed understanding of underlying immunopathology, advanced knowledge of clinical and basic science and translational research, and the capability to evaluate the available evidence. The immunotherapy guideline development group, composed of clinical reproductive immunology fellows, ASRI, reviewed the currently available data and developed the clinical guidelines for immunotherapy.
- 30 May 2025
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 93 (6) , e70099
2025 American Society for Reproductive Immunology Guidelines for the Treatment of Recurrent Pregnancy Losses: Practice Recommendations From the ASRI Clinical Reproductive Immunology Fellowship
Various immunomodulatory treatments have been applied to women with recurrent pregnancy losses since a significant proportion of them have cellular and autoimmune abnormalities. However, immunomodulatory treatments are often considered controversial for their efficacies. Often, they are provided to unselected patients without investigating potential etiologies by healthcare providers without appropriate reproductive immunology training and qualifications. To eliminate these concerns, the American Society for Reproductive Immunology (ASRI) established the Clinical Reproductive Immunology Fellowship and has been certifying reproductive immunologists. The approach to RPL from a reproductive immunology perspective requires a detailed understanding of underlying immunopathology, advanced knowledge of clinical and basic science and translational research, and the capability to evaluate the available evidence. The immunotherapy guideline development group, composed of clinical reproductive immunology fellows, ASRI, reviewed the currently available data and developed the clinical guidelines for immunotherapy.
- Open Access
- 24 October 2024
- Published by Peertechz Publications Private Limited in Journal of Gynecological Research and Obstetrics
- Vol. 10 (2) , 031-039
Mild Ovarian Stimulation Using the Aromatase Inhibitor Letrozole (LTZ) is a Good Stimulation Protocol for to Obtain Euploid Blastocysts for Advanced Maternal Age Women
Purpose: Mild Ovarian Stimulation (MOS) is an effective form of Assisted Reproductive Technology (ART) for Advanced Maternal Age (AMA) women. Taking either Clomiphene (CC) or Letrozole (LTZ) with MOS reduces the amount of gonadotropin that must be used. It has remained uncertain, however, whether LTZ or CC is more effective in combination with MOS. Therefore, we evaluated the choice of combination of either CC or LTZ with MOS and quantified the obtainment of euploid blastocysts for AMA women. Methods: This retrospective study was conducted between January 2020 and April 2021. In this study, we stimulated 286 women with MOS, 153 of these women used CC (CC group) and 133 were given LTZ (LTZ group). All women took either 100 mg of CC or 5 mg of LTZ daily for 7 days between MC 3 and MC 9, and 225 IU of recombinant-FSH were administered on MC 3, MC 5, MC 7, and MC 9. The euploid rates were compared between these two groups. Among them, the women who were ≥ 40 years old were divided into two groups, the CC-O40 group (n = 61) and LTZ-O40 group (n = 54), and the euploid rates were evaluated. Results: For AMA women, the blastocyst formation rate in the LTZ-O40 group (58.5%) was significantly higher than that in the CC-O40 group (46.6%, p < 0.05). The euploid rate in the LTZ group was 53.4%, which was significantly higher than that in the CC group (38.0%, p < 0.05). The AMA euploid rate in the LTZ-O40 group was 40.5%, which also was significantly higher than that in the CC-O40 group (16.7%, p < 0.05). Conclusions: For AMA women, a regimen of LTZ combined with MOS is the most effective ovarian stimulation method for obtaining euploid blastocysts.
- 24 October 2024
- Published by Peertechz Publications Private Limited in Journal of Gynecological Research and Obstetrics
- Vol. 10 (2) , 031-039
Open AccessMild Ovarian Stimulation Using the Aromatase Inhibitor Letrozole (LTZ) is a Good Stimulation Protocol for to Obtain Euploid Blastocysts for Advanced Maternal Age Women
Purpose: Mild Ovarian Stimulation (MOS) is an effective form of Assisted Reproductive Technology (ART) for Advanced Maternal Age (AMA) women. Taking either Clomiphene (CC) or Letrozole (LTZ) with MOS reduces the amount of gonadotropin that must be used. It has remained uncertain, however, whether LTZ or CC is more effective in combination with MOS. Therefore, we evaluated the choice of combination of either CC or LTZ with MOS and quantified the obtainment of euploid blastocysts for AMA women. Methods: This retrospective study was conducted between January 2020 and April 2021. In this study, we stimulated 286 women with MOS, 153 of these women used CC (CC group) and 133 were given LTZ (LTZ group). All women took either 100 mg of CC or 5 mg of LTZ daily for 7 days between MC 3 and MC 9, and 225 IU of recombinant-FSH were administered on MC 3, MC 5, MC 7, and MC 9. The euploid rates were compared between these two groups. Among them, the women who were ≥ 40 years old were divided into two groups, the CC-O40 group (n = 61) and LTZ-O40 group (n = 54), and the euploid rates were evaluated. Results: For AMA women, the blastocyst formation rate in the LTZ-O40 group (58.5%) was significantly higher than that in the CC-O40 group (46.6%, p < 0.05). The euploid rate in the LTZ group was 53.4%, which was significantly higher than that in the CC group (38.0%, p < 0.05). The AMA euploid rate in the LTZ-O40 group was 40.5%, which also was significantly higher than that in the CC-O40 group (16.7%, p < 0.05). Conclusions: For AMA women, a regimen of LTZ combined with MOS is the most effective ovarian stimulation method for obtaining euploid blastocysts.
- 18 October 2024
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 92 (4) , e70002
Analysis of the Predictive Factors for Chronic Endometritis Recurrence in Infertile Women
Problem: To identify the predictive factors for the recurrence of chronic endometritis (CE) in infertile women.Method of study: In this case‐control study, 1170 infertile women recovered from CE and underwent fertility treatment between December 2018 and August 2021. Among the 146 women (12.5%) who did not conceive or experienced pregnancy loss in 18 months after CE recovery, 105 consecutive women who underwent repeat endometrial biopsy for CD138 immunostaining and endometrial bacterial culturing were recruited. Thereafter, patients with and without CE recurrence were compared.Results: The total recurrence rate of CE was 29.5% (31 women). Multivariable logistic regression analysis to determine predictive factors for CE recurrence revealed that hysteroscopic surgery (odds ratio [OR], 0.10; 95% confidence interval [CI], 0.02–0.56; p = 0.0009) and pregnancy loss (OR, 4.13; 95% CI, 1.31–13.05; p = 0.016) were significantly associated with decreased and increased CE recurrence rates, respectively. Also, reexamination with CD138 immunostaining after 16–18 months (OR, 9.75; 95% CI, 1.47–64.64; p = 0.024) was significantly associated with increased CE recurrence rates. Among 49 patients without a history of pregnancy loss, the cumulative CE recurrence rates after 6, 12, and 18 months were 5.6%, 13.5%, and 20.4%, respectively.Conclusions: We recommend reexamination with endometrial CD138 immunostaining in patients with pregnancy loss or long‐term infertility during fertility treatment. Hysteroscopic surgery without antibiotic therapy for CE associated with intrauterine abnormalities is also recommended.
- 18 October 2024
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 92 (4) , e70002
Analysis of the Predictive Factors for Chronic Endometritis Recurrence in Infertile Women
Problem: To identify the predictive factors for the recurrence of chronic endometritis (CE) in infertile women.Method of study: In this case‐control study, 1170 infertile women recovered from CE and underwent fertility treatment between December 2018 and August 2021. Among the 146 women (12.5%) who did not conceive or experienced pregnancy loss in 18 months after CE recovery, 105 consecutive women who underwent repeat endometrial biopsy for CD138 immunostaining and endometrial bacterial culturing were recruited. Thereafter, patients with and without CE recurrence were compared.Results: The total recurrence rate of CE was 29.5% (31 women). Multivariable logistic regression analysis to determine predictive factors for CE recurrence revealed that hysteroscopic surgery (odds ratio [OR], 0.10; 95% confidence interval [CI], 0.02–0.56; p = 0.0009) and pregnancy loss (OR, 4.13; 95% CI, 1.31–13.05; p = 0.016) were significantly associated with decreased and increased CE recurrence rates, respectively. Also, reexamination with CD138 immunostaining after 16–18 months (OR, 9.75; 95% CI, 1.47–64.64; p = 0.024) was significantly associated with increased CE recurrence rates. Among 49 patients without a history of pregnancy loss, the cumulative CE recurrence rates after 6, 12, and 18 months were 5.6%, 13.5%, and 20.4%, respectively.Conclusions: We recommend reexamination with endometrial CD138 immunostaining in patients with pregnancy loss or long‐term infertility during fertility treatment. Hysteroscopic surgery without antibiotic therapy for CE associated with intrauterine abnormalities is also recommended.
- Open Access
- 20 August 2024
- Published by European Medical Group in EMJ Reproductive Health
- Vol. 10 (1) , 34-36
Tacrolimus Treatment Improved Pregnancy Rate with Euploid Blastocyst in Women with Repeated Implantation Failures and Elevated T Helper 1/2 Cell Ratios
In organ transplantation, the transplanted organ is usually attacked by various lymphocytes. In contrast, a transferred embryo might be...
- 20 August 2024
- Published by European Medical Group in EMJ Reproductive Health
- Vol. 10 (1) , 34-36
Open AccessTacrolimus Treatment Improved Pregnancy Rate with Euploid Blastocyst in Women with Repeated Implantation Failures and Elevated T Helper 1/2 Cell Ratios
In organ transplantation, the transplanted organ is usually attacked by various lymphocytes. In contrast, a transferred embryo might be...
- Open Access
- 13 March 2024
- Published by Springer Nature in Research Square
Mild ovarian stimulation using the aromatase inhibitor letrozole (LTZ) is a good stimulation protocol for to obtain euploid blastocysts for advanced maternal age women.
Purpose: Mild ovarian stimulation (MOS) is an effective form of assisted reproductive technology (ART) for advanced maternal age (AMA) women. Taking either clomiphene (CC) or letrozole (LTZ) with MOS reduces the amount of gonadotropin that must be used. It has remained uncertain, however, whether LTZ or CC is more effective in combination with MOS. Therefore, we evaluated the choice of combination either CC or LTZ with MOS and quantified the obtainment of euploid blastocysts for AMA women. Methods This retrospective study was conducted between January 2020 and April 2021. In this study, we stimulated 286 women with MOS, 153 of these women used CC (CC group) and 133 were given LTZ (LTZ group). All women took either 100 mg of CC or 5 mg of LTZ daily for 7 days between MC 3 and MC 9, and 225 IU of recombinant-FSH were administered on MC 3, MC 5, MC 7, and MC 9. The euploid rates were compared between these two groups. Among them, the women who were ≥ 40 years old were divided into two groups, CC-O40 group (n = 61) and LTZ-O40 group (n = 54), and the euploid rates were evaluated. Results: For AMA women, the blastocyst formation rate in the LTZ-O40 group (58.5%) was significantly higher than that in the CC-O40 group (46.6%, P < 0.05). The euploid rate in the LTZ group was 53.4%, which was significantly higher than that in the CC group (38.0%, P < 0.05). The AMA euploid rate in the LTZ-O40 group was 40.5%, which also was significantly higher than that in the CC-O40 group (16.7%, P < 0.05). Conclusions For AMA women, a regimen of LTZ combined with MOS is the most effective ovarian stimulation method for obtaining euploid blastocysts.
- 13 March 2024
- Published by Springer Nature in Research Square
Open AccessMild ovarian stimulation using the aromatase inhibitor letrozole (LTZ) is a good stimulation protocol for to obtain euploid blastocysts for advanced maternal age women.
Purpose: Mild ovarian stimulation (MOS) is an effective form of assisted reproductive technology (ART) for advanced maternal age (AMA) women. Taking either clomiphene (CC) or letrozole (LTZ) with MOS reduces the amount of gonadotropin that must be used. It has remained uncertain, however, whether LTZ or CC is more effective in combination with MOS. Therefore, we evaluated the choice of combination either CC or LTZ with MOS and quantified the obtainment of euploid blastocysts for AMA women. Methods This retrospective study was conducted between January 2020 and April 2021. In this study, we stimulated 286 women with MOS, 153 of these women used CC (CC group) and 133 were given LTZ (LTZ group). All women took either 100 mg of CC or 5 mg of LTZ daily for 7 days between MC 3 and MC 9, and 225 IU of recombinant-FSH were administered on MC 3, MC 5, MC 7, and MC 9. The euploid rates were compared between these two groups. Among them, the women who were ≥ 40 years old were divided into two groups, CC-O40 group (n = 61) and LTZ-O40 group (n = 54), and the euploid rates were evaluated. Results: For AMA women, the blastocyst formation rate in the LTZ-O40 group (58.5%) was significantly higher than that in the CC-O40 group (46.6%, P < 0.05). The euploid rate in the LTZ group was 53.4%, which was significantly higher than that in the CC group (38.0%, P < 0.05). The AMA euploid rate in the LTZ-O40 group was 40.5%, which also was significantly higher than that in the CC-O40 group (16.7%, P < 0.05). Conclusions For AMA women, a regimen of LTZ combined with MOS is the most effective ovarian stimulation method for obtaining euploid blastocysts.
- Open Access
- 9 January 2024
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 23 (1) , e12558
Tacrolimus treatment in women with repeated implantation failures
Background: Tacrolimus is an immunosuppressive drug that works as a calcineurin inhibitor to improve the reproductive outcomes for women who have experienced multiple implantation failures (RIF) and show elevated type 1 helper T (Th1)/Th2 cell ratios.Methods: In the first part of this review, we indicate how we re‐evaluated the cut‐off index for selecting the participants in a tacrolimus regimen via transferred euploid blastocysts. In the second part, we cite cases where tacrolimus has improved the live birth rate for women who have experienced recurrent pregnancy losses (PRL) and we introduce the utility of tacrolimus treatment to prevent obstetrical complications.Main Findings: After reconsideration of the cut‐off index (Th1/Th2 ≥ 11.8), however, the pregnancy rates of women with tacrolimus were significantly higher than those of women without tacrolimus. The PRL women treated with tacrolimus showed significantly lower rates of biochemical pregnancy, but higher live‐birth rates compared with women who were not treated with tacrolimus. Moreover, prior severe obstetrical complications could be controlled via the administration of tacrolimus during pregnancy.Conclusion: Tacrolimus has become indispensable in the field of solid‐organ transplantation, and in the near future, it should become an essential agent in the reproductive field, as well.
- 9 January 2024
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 23 (1) , e12558
Open AccessTacrolimus treatment in women with repeated implantation failures
Background: Tacrolimus is an immunosuppressive drug that works as a calcineurin inhibitor to improve the reproductive outcomes for women who have experienced multiple implantation failures (RIF) and show elevated type 1 helper T (Th1)/Th2 cell ratios.Methods: In the first part of this review, we indicate how we re‐evaluated the cut‐off index for selecting the participants in a tacrolimus regimen via transferred euploid blastocysts. In the second part, we cite cases where tacrolimus has improved the live birth rate for women who have experienced recurrent pregnancy losses (PRL) and we introduce the utility of tacrolimus treatment to prevent obstetrical complications.Main Findings: After reconsideration of the cut‐off index (Th1/Th2 ≥ 11.8), however, the pregnancy rates of women with tacrolimus were significantly higher than those of women without tacrolimus. The PRL women treated with tacrolimus showed significantly lower rates of biochemical pregnancy, but higher live‐birth rates compared with women who were not treated with tacrolimus. Moreover, prior severe obstetrical complications could be controlled via the administration of tacrolimus during pregnancy.Conclusion: Tacrolimus has become indispensable in the field of solid‐organ transplantation, and in the near future, it should become an essential agent in the reproductive field, as well.
- Open Access
- 7 December 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (24) , 7152
Risk Factors for Alcohol Consumption after Starting Assisted Reproductive Technology Treatment among Japanese Women: Japan-Female Employment and Mental Health in Assisted Reproductive Technology (J-FEMA) Study
Aims: To determine the association between drinking habits and social factors among women undergoing assisted reproductive technology (ART) treatment in Japan. Methods: The study participants who provided answers for the questionnaire concerning alcohol consumption were 1017 female patients undergoing ART treatment were enrolled in the Japan-Female Employment and Mental Health in assisted reproductive technology (J-FEMA) study between August and December 2018. Patient characteristics, including demographic, clinical, and socioeconomic status, were assessed using a self-administered questionnaire which was distributed only once during the period, regardless of their first or follow-up examination. We defined current drinkers who drank ≥46 g of ethanol per week as the habitual drinking group. The risk factors for habitual drinking were analyzed using multivariable-adjusted logistic regression. Results: The proportion of habitual drinkers was 15.5% in this study population. The multivariable-adjusted odds ratios (95% confidence interval) for habitual drinking were 2.27 (0.99–5.21) for women aged ≥35 years versus those <35 years, 4.26 (1.98–9.16) for women having partners who currently drink compared to those with partners without current drinking, 1.84 (1.08–3.12) for women without a history of childbirth versus those with, and 1.77 (1.00–3.14) for working women compared with those not working. Conclusions: In our study, habitual drinking among women undergoing ART treatment was significantly associated with older age, no history of childbirth, partner’s current drinking status, and working.
- 7 December 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (24) , 7152
Open AccessRisk Factors for Alcohol Consumption after Starting Assisted Reproductive Technology Treatment among Japanese Women: Japan-Female Employment and Mental Health in Assisted Reproductive Technology (J-FEMA) Study
Aims: To determine the association between drinking habits and social factors among women undergoing assisted reproductive technology (ART) treatment in Japan. Methods: The study participants who provided answers for the questionnaire concerning alcohol consumption were 1017 female patients undergoing ART treatment were enrolled in the Japan-Female Employment and Mental Health in assisted reproductive technology (J-FEMA) study between August and December 2018. Patient characteristics, including demographic, clinical, and socioeconomic status, were assessed using a self-administered questionnaire which was distributed only once during the period, regardless of their first or follow-up examination. We defined current drinkers who drank ≥46 g of ethanol per week as the habitual drinking group. The risk factors for habitual drinking were analyzed using multivariable-adjusted logistic regression. Results: The proportion of habitual drinkers was 15.5% in this study population. The multivariable-adjusted odds ratios (95% confidence interval) for habitual drinking were 2.27 (0.99–5.21) for women aged ≥35 years versus those <35 years, 4.26 (1.98–9.16) for women having partners who currently drink compared to those with partners without current drinking, 1.84 (1.08–3.12) for women without a history of childbirth versus those with, and 1.77 (1.00–3.14) for working women compared with those not working. Conclusions: In our study, habitual drinking among women undergoing ART treatment was significantly associated with older age, no history of childbirth, partner’s current drinking status, and working.